Characteristics, treatment distribution and outcome in AML patients aged 70 years and older: a study from a large data set from DATAML, SAL and PETHEMA registries Christian Récher, MD, PhD, Service d’Hématologie, Centre Hospitalier Universitaire de...
More
Characteristics, treatment distribution and outcome in AML patients aged 70 years and older: a study from a large data set from DATAML, SAL and PETHEMA registries Christian Récher, MD, PhD, Service d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France Emilie Bérard, MD, PhD, Unité de Soutien Méthodologique à la Recherche, Centre Hospitalier Universitaire de Toulouse, Toulouse, France Rationale and Background The incidence of acute myeloid leukemia (AML) increases with age, with a median age of 68-70 years at diagnosis. In contrast with younger patients whose prognostic has improved overtime, patients over the age of 70y continue to have poor outcome even if they are fit for intensive treatment. AML in older patients are more frequently associated with adverse factors including chemoresistance, unfavorable cytogenetics, and increased frequency of somatic mutations as well as previous history of myelodysplasti
Less
